Engex, Inc. (EGX) 뉴스

Walter, have you been able to speak with Michael since his departure from the company and if so would you be willing to share with us any insight from that conversation as it relates to Lightwave.

You have to remember all of the misleading that was done on his part,

Claimed in 2016 that Nioturd was on the cusp of full and complete funding, then claimed just a few years ago how the NASDAQ was going to be the game changer. Both turned out to be false and very misleading.

Why are you and Price and Homebrew the Warrior Moderator so lonely that you have to hang around a DEAD stock board?

Can you explain what you meant by this line?  
style="caret-color: rgb(29, 38, 46); color: rgba(29, 38, 46, 1); font-family: DMSans-Regular, sans-serif; font-size: 15px"

style="caret-color: rgb(29, 38, 46); color: rgba(29, 38, 46, 1); font-family: DMSans-Regular, sans-seri

not bad, like 1% of float

People make their own choices....I've never seen ANY pumping here

Is this company named after Knight Rider?

Do you see the stakes being raised to include spillover into criminal investigations?

Thx

GLTA

goooooooooooooooooooooooood morning bobber

Great findings Mrwrn2010!!!!

GOOD MORNING EVERYONE 

GO $MCIC 

VMAR.......KULR......BMRA......PRCH.......ULY.......ATCH........https://stockcharts.com/h-sc/ui?s=ATCH&p=D&yr=0&mn=2&dy=12&id=p84071410134

SNOW
Snowflake price target raised to $203 from $190 at Barclays
Barclays raised the firm's price target on Snowflake to $203 from $190 and keeps an Overweight rating on the shares. The company reported a "healthy" Q4 and delivered fiscal 2026 sales guidance ahead of Street expectat

Starting to panic? Pity, really.

Several Dairy Queen groups are closing/filing bankruptcy. Don't worry. Everything is fine. Idiots.

Hope you bought 
$RILY at 3 or 4 
🤭🚀💵

B. Riley Financial Announces $160 Million Debt Financing Provided by Oaktree

NVDA
Nvidia price target raised to $162 from $152 at Morgan Stanley
Morgan Stanley raised the firm's price target on Nvidia to $162 from $152 and keeps an Overweight rating on the shares. Q4 revenues were slightly better than the firm previewed, with gross margins slightly worse, th

Rnaz will bounce higher today. Go. Rnaz

Well....it remains safe...not all endpoints (especially the failed primary endpoints) or the placebo arm point to effective for AD...and definitely not effective for Rett. Trials for PD took forever to get going and still aren't started...What are they hiding?

Doesn't matter the science. This is a business. Gotta follow the Benjamins. That's all that matters

2.89 is a gift i added. 800. Shares.  Go. RNAZ

hyperopia, thx much for the factual response. Your patience, technical understanding and writing are very helpful to all here.
Given the timing now vs when NWBO published their 2/24 PR, do you think it is too optimistic to think the re-inspection may have been due to FW qualification?